Presented by Allie Cummings, B.S., HT(ASCP), Agilent
Technologies
Predictive biomarker testing to inform treatment decision-making has radically influenced the practice of both pathology and oncology today. As the
treatment scenario evolves, choosing the appropriate biomarker to select the right patients become vital. In this talk we will review the most up-to-date FDA approvals for checkpoint inhibitors and
PD-L1 companion diagnostic assays. We will then compare the different PD-L1 scoring systems (TPS, CPS, IC, TC) and point out the role of clinical validation of PD-L1 assays. Finally, we will look at
the future of cancer targeted therapies and emerging biomarkers.
This webinar is part of the 2021 Laboratory
Webinar Series.
Laboratory Webinars are a great, inexpensive way to provide continuing education to a large number of employees.
The cost for each session is the same
regardless of the number of attendees.
*Earn CEU's - One CEU per attendee per session
*Group Learning - Unlimited # of participants for one low fee
*Archive Sessions -
Archived materials are available for 1 year to train new staff - AND STILL EARN CEUs!
NEW
affordable and flexible pricing!
- Early Bird (more than 30 days in advance) - $79.00
- Regular
(month of live event) - $99.00
- Late (30 days after or later) - $125.00
Any questions please contact
the NSH Office, 443-535-4060 or histo@nsh.org.